BRISTOL-MYERS SQUIBB COMPANY Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) of -$27.00 million for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-12.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss · last filed 2016-02-12
- BRISTOL-MYERS SQUIBB COMPANY fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for fiscal 2015 was -$27.00M.
- BRISTOL-MYERS SQUIBB COMPANY fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for fiscal 2014 was -$8.00M, a 120.00% decline from fiscal 2013.
- BRISTOL-MYERS SQUIBB COMPANY fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for fiscal 2013 was $40.00M.
- BRISTOL-MYERS SQUIBB COMPANY fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for fiscal 2012 was -$49.00M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) 12 month |
|---|---|
| 2015-12-31 | -$27.00M 10-K · filed 2016-02-12 |
| 2014-12-31 | -$8.00M 10-K · filed 2016-02-12 |
| 2013-12-31 | $40.00M 10-K · filed 2015-02-13 |
| 2012-12-31 | -$49.00M 10-K · filed 2014-02-14 |
| 2011-12-31 | -$66.00M 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |